Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
B'Okcares Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. Prosecution is concentrated under 1 distinct examiner and 1 distinct art unit. BAEK, JONGHWAN NMN is the busiest examiner, with 1 busiest examiner pending office action currently assigned. The company's 1 pending office action is the sole focus of its current patent office activity. By working with only 1 distinct examiner, the applicant can tailor its responses to the specific feedback of BAEK, JONGHWAN NMN.
This concentration in 1 distinct art unit simplifies the administrative burden but concentrates the risk of the prosecution on a single examiner's decision. The 1 busiest examiner pending action represents the entirety of the current pipeline. Practitioners should note that having 1 distinct examiner means there is no opportunity to compare examination styles within the portfolio. The focus on the Biotechnology & Pharmaceuticals field suggests that the company's current research and development are highly specialized. Successfully resolving the 1 pending office action is the immediate priority for securing the company's intellectual property rights.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAEK, JONGHWAN NMN | 1 | 50.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18207184 | Homeopathic mixture for relieving general fatigue symptoms and cancer treatment related fatigue symptoms | BAEK, JONGHWAN NMN | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18207184 | Homeopathic mixture for relieving general fatigue symptoms and cancer treatment related fatigue symptoms | BAEK, JONGHWAN NMN | 1618 | §103§112 | Final Rejection | — | Pending | Jun 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialB'Okcares Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Jonghwan Nmn Baek has the most, with 1 of B'Okcares Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.